You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDapiprazole
Accession NumberDB00298  (APRD00902)
TypeSmall Molecule
GroupsApproved
DescriptionDapiprazole (U.S. trade name Rev-Eyes) is an alpha blocker. It is used to reverse mydriasis after eye examination. [Wikipedia]
Structure
Thumb
Synonyms
5,6,7,8-Tetrahydro-3-(2-(4-(O-tolyl)-1-piperazinyl)ethyl)-S-triazolo(4,3-a)pyridine
Dapiprazol
Dapiprazolum
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Rev-EyesNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Dapiprazole hydrochloride
ThumbNot applicableDBSALT001438
Categories
UNII5RNZ8GJO7K
CAS number72822-12-9
WeightAverage: 325.4512
Monoisotopic: 325.226645889
Chemical FormulaC19H27N5
InChI KeyRFWZESUMWJKKRN-UHFFFAOYSA-N
InChI
InChI=1S/C19H27N5/c1-16-6-2-3-7-17(16)23-14-12-22(13-15-23)11-9-19-21-20-18-8-4-5-10-24(18)19/h2-3,6-7H,4-5,8-15H2,1H3
IUPAC Name
1-(2-methylphenyl)-4-(2-{5H,6H,7H,8H-[1,2,4]triazolo[4,3-a]pyridin-3-yl}ethyl)piperazine
SMILES
CC1=CC=CC=C1N1CCN(CCC2=NN=C3CCCCN23)CC1
Pharmacology
IndicationUsed in the treatment of iatrogenically induced mydriasis produced by adrenergic (phenylephrine) or parasympatholytic (tropicamide) agents used in certain eye examinations.
Structured Indications Not Available
PharmacodynamicsDapiprazole is an alpha-adrenergic blocking agent. It produces miosis by blocking the alpha-adrenergic receptors on the dilator muscle of the iris. Dapiprazole produces no significant action on ciliary muscle contraction and thus, there are no changes in the depth of the anterior chamber of the thickness of the lens. It does not alter the IOP either in normal eyes or in eyes with elevated IOP. The rate of pupillary constriction may be slightly slower in clients with brown irises than in clients with blue or green irises.
Mechanism of actionDapiprazole acts through blocking the alpha1-adrenergic receptors in smooth muscle. It produces miosis through an effect on the dilator muscle of the iris and does not have any significant activity on ciliary muscle contraction and, therefore does not induce a significant change in the anterior chamber depth or the thickness of the lens.
TargetKindPharmacological actionActionsOrganismUniProt ID
Alpha-1A adrenergic receptorProteinyes
antagonist
HumanP35348 details
Alpha-1D adrenergic receptorProteinyes
antagonist
HumanP25100 details
Alpha-1B adrenergic receptorProteinyes
antagonist
HumanP35368 details
Related Articles
AbsorptionSystemic absorption is negligible.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityOral LD50 is 1189-2100 mg/kg in mice, rats and rabbits.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamineDapiprazole may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineDapiprazole may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetamineDapiprazole may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineDapiprazole may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Aceprometazine.Approved
adipiplonThe risk or severity of adverse effects can be increased when Dapiprazole is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Alfentanil.Approved, Illicit
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Dapiprazole.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Alprazolam.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Amperozide.Experimental
AmphetamineDapiprazole may decrease the stimulatory activities of Amphetamine.Approved, Illicit
AripiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Aripiprazole.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Asenapine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Azaperone.Vet Approved
AzelastineDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Benzocaine.Approved
BenzphetamineDapiprazole may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Benzyl alcohol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved
BromazepamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Bromazepam.Approved, Illicit
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Dapiprazole.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dapiprazole.Approved, Investigational
BuprenorphineDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dapiprazole.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Butorphanol.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Dapiprazole.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Carisoprodol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Chlordiazepoxide.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Chloroprocaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Chlorphenamine.Approved
ChlorphentermineDapiprazole may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Dapiprazole.Approved
ClemastineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Clorazepate.Approved, Illicit
ClozapineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Clozapine.Approved
CocaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Codeine.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Cyclobenzaprine.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dantrolene.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dapoxetine.Investigational
deramciclaneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Dapiprazole.Approved
DetomidineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineDapiprazole may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Dapiprazole.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Diazepam.Approved, Illicit, Vet Approved
DiethylpropionDapiprazole may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Dapiprazole.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Diphenoxylate.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Dapiprazole is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Dapiprazole.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Dapiprazole is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Dapiprazole.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Dapiprazole.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Entacapone.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Dapiprazole.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Dapiprazole.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Dapiprazole.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Dapiprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Eszopiclone.Approved
EthanolDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dapiprazole.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Dapiprazole.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Dapiprazole.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fluticasone Propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dapiprazole.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Dapiprazole.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Dapiprazole is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Hexobarbital.Approved
HydrocodoneDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Hydromorphone.Approved, Illicit
Hydroxyamphetamine hydrobromideDapiprazole may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Indalpine.Investigational, Withdrawn
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Dapiprazole.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Isoflurane.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ketobemidone.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Dapiprazole.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Dapiprazole.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Dapiprazole.Approved, Investigational
LisdexamfetamineDapiprazole may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Dapiprazole.Approved
LofentanilThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Lofentanil.Illicit
LoratadineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dapiprazole.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Dapiprazole.Approved
LoxapineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Loxapine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Dapiprazole is combined with Lu AA21004.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Melperone.Approved
MephedroneDapiprazole may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineDapiprazole may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Meprobamate.Approved, Illicit
MequitazineDapiprazole may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineDapiprazole may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methohexital.Approved
MethotrimeprazineDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methsuximide.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methylphenobarbital.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Dapiprazole.Approved, Investigational
MetyrosineDapiprazole may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Midazolam.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Dapiprazole.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved, Investigational
MirtazapineDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDADapiprazole may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Dapiprazole.Approved
MolindoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Dapiprazole.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Nalbuphine.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Dapiprazole.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Dapiprazole.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Olanzapine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Opium.Approved, Illicit
OrphenadrineDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Oxymorphone.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Paliperidone.Approved
ParaldehydeDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Dapiprazole.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved
PerazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Pethidine.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Dapiprazole.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Phenoxyethanol.Approved
PhentermineDapiprazole may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Pomalidomide.Approved
PramipexoleDapiprazole may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Dapiprazole.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Dapiprazole.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Prochlorperazine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Dapiprazole is combined with PSD502.Investigational
PseudoephedrineDapiprazole may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Quetiapine.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Dapiprazole.Approved
RacloprideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ramelteon.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Dapiprazole.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dapiprazole.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ritanserin.Investigational
RitobegronDapiprazole may decrease the stimulatory activities of Ritobegron.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Dapiprazole.Approved
RomifidineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Romifidine.Vet Approved
RopiniroleDapiprazole may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dapiprazole.Approved
RotigotineDapiprazole may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Dapiprazole.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Dapiprazole is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Dapiprazole is combined with Sage 547.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Dapiprazole.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Dapiprazole.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Sevoflurane.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved
StiripentolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Sufentanil.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Sulpiride.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Dapiprazole.Approved, Investigational
SuvorexantDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Dapiprazole.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Dapiprazole.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Dapiprazole.Approved
TetracaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tetrodotoxin.Investigational
ThalidomideDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Thioridazine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tiapride.Investigational
TiletamineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tiletamine.Vet Approved
TizanidineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Dapiprazole.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Triazolam.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Dapiprazole is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Valproic Acid.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Dapiprazole.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Dapiprazole.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Dapiprazole.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Dapiprazole.Approved, Investigational
ZolpidemDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesS01EX02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (114 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9832
Caco-2 permeable+0.5899
P-glycoprotein substrateSubstrate0.657
P-glycoprotein inhibitor IInhibitor0.8074
P-glycoprotein inhibitor IIInhibitor0.9107
Renal organic cation transporterInhibitor0.7481
CYP450 2C9 substrateNon-substrate0.8296
CYP450 2D6 substrateNon-substrate0.5563
CYP450 3A4 substrateSubstrate0.5833
CYP450 1A2 substrateInhibitor0.6905
CYP450 2C9 inhibitorNon-inhibitor0.5324
CYP450 2D6 inhibitorNon-inhibitor0.632
CYP450 2C19 inhibitorInhibitor0.7506
CYP450 3A4 inhibitorInhibitor0.7338
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9357
Ames testNon AMES toxic0.6215
CarcinogenicityNon-carcinogens0.8546
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7573 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6592
hERG inhibition (predictor II)Inhibitor0.7292
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Angelini pharmaceuticals inc
Packagers
  • American Cyanamid Co.
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilitySolubleNot Available
logP2.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.751 mg/mLALOGPS
logP2.78ALOGPS
logP2.42ChemAxon
logS-2.6ALOGPS
pKa (Strongest Basic)7.67ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area37.19 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity100.22 m3·mol-1ChemAxon
Polarizability38.23 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazinanes
Sub ClassPiperazines
Direct ParentPhenylpiperazines
Alternative Parents
Substituents
  • N-arylpiperazine
  • Phenylpiperazine
  • Triazolopyridine
  • Aminotoluene
  • Substituted aniline
  • Dialkylarylamine
  • Aralkylamine
  • N-alkylpiperazine
  • Toluene
  • Aniline
  • Benzenoid
  • Pyridine
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • 1,2,4-triazole
  • Triazole
  • Azole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Eltze M: Affinity of the miotic drug, dapiprazole, at alpha 1-adrenoceptor subtypes A, B and D. J Pharm Pharmacol. 1997 Nov;49(11):1091-5. [PubMed:9401944 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23